pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
CRL (Complete Response Letter) · news · pharmadog
← back to CRL (Complete Response Letter)
News · CRL (Complete Response Letter)
52
stories
May 8, 26
UT MD Anderson Shares Latest Research Breakthroughs
onclive
May 8, 26
Giants of Cancer Care Announces the 14th Annual Class of Inductees
onclive
May 8, 26
OncLive Weekly News Quiz (5/8/2026): Test Your Knowledge on Key Breast, Lung, and Pancreatic Cancer Updates
onclive
May 8, 26
OncLive Polls Reveal Picks for Top Lung Cancer Abstracts at ASCO 2026
onclive
May 8, 26
Poll Results Highlight Breast Cancer Abstracts of Interest at ASCO 2026
onclive
May 8, 26
Dr Gruenbaum on Where Alternative Options to BTK Inhibitors Stand in MCL
onclive
May 7, 26
Sylvester Comprehensive Cancer Center Identifies a Screening Gap to Prevent a Type of Leukemia in the U.S.
onclive
May 7, 26
FDA Completes Type A Meeting Following CRL for Tabelecleucel in EBV+ R/R Post-Transplant Lymphoproliferative Disease
onclive
May 7, 26
ASCO 2026 TNBC Deep Dive: Breast Cancer Experts Preview Practice-Informing Studies
onclive
May 7, 26
Track the Lung Cancer Abstracts That are Gaining Attention at ASCO 2026
onclive
May 7, 26
Reigniting Your Curiosity During Fellowship
onclive
May 6, 26
Dr Chari on Frontline Combinations and Transplant Approaches in Multiple Myeloma
onclive
May 6, 26
Cases and Conversations™: Next-Generation Pathology Advances and Considerations for Precision Care in Non–Small Cell Lung Cancer
onclive
May 6, 26
Dr Herrera on the Significance of the FDA Approval of Nivolumab Plus AVD for Classical Hodgkin Lymphoma
onclive
May 6, 26
Dr Sznol on Biomarkers of Response in Metastatic Melanoma
onclive
May 6, 26
Transformational Utah Investment in Artificial Intelligence and Computing to Advance Health and Discovery
onclive
May 6, 26
ASCO 2026 HR+ and HER2+ Breast Cancer Preview: Read up on the Insights to Know Before You Go
onclive
May 6, 26
Disease Assessment and Mutational Testing in Progressive CLL
onclive
May 6, 26
Clinical Scenario Presentation and Treatment Approach for Progressive Disease
onclive
May 6, 26
Dr Pant on the Mechanism of Action of Daraxonrasib in PDAC
onclive
May 5, 26
Dr Cohen on Frontline Chemotherapy Selection in Metastatic Pancreatic Cancer
onclive
Apr 24, 26
Sanofi’s tolebrutinib gets CHMP backing for certain MS patients despite FDA rejection
endpoints
← prev
page 2 of 2
next →
